Abstract
Objectives In most European countries, patients seeking medication abortion during the COVID-19 pandemic are still expected to attend healthcare settings in person despite lockdown measures and infection risk. We assessed whether demand for self-managed medication abortion provided by a fully remote online telemedicine service increased following the emergence of COVID-19.
Design We used regression discontinuity to compare the number of requests to online telemedicine service Women on Web in eight European countries before and after they implemented lockdown measures to slow COVID-19 transmission. We examined the number deaths due to COVID-19, the degree of government-provided economic support, the severity of lockdown travel restrictions, and the medication abortion service provision model in countries with and without significant changes in requests.
Setting Eight European countries served by Women on Web.
Participants 3,915 people who made requests for self-managed abortion to Women on Web between January 1st, 2019 and June 1st, 2020.
Main Outcome Measures Percent change in requests to Women on Web before and after the emergence of COVID-19 and associated lockdown measures.
Results Five countries showed significant increases in requests, ranging from 28% in Northern Ireland (p=0.001) to 139% in Portugal (p<0.001). Two countries showed no significant change in requests, and one country, Great Britain, showed an 88% decrease in requests (p<0.001). Countries with significant increases in requests were either countries where abortion services are mainly provided in hospitals or where no abortion services are available and international travel was prohibited during lockdown. By contrast, Great Britain authorized teleconsultation for medication abortion and provision of medications by mail during the pandemic.
Conclusion These marked changes in requests for self-managed medication abortion during COVID-19 demonstrate demand for fully remote models of abortion care and an urgent need for policymakers to expand access to medication abortion by telemedicine.
What is already know on this subject
What is already know on this subject
The COVID-19 pandemic has presented challenges to patients seeking medication abortion, including lockdown travel restrictions and infection risk during in-person clinic visits.
Yet in most European countries, medication abortion must still be provided through in-person models of care. The sole exception is Great Britain, where a fully remote medication abortion service was introduced in response to the pandemic.
Anecdotal reports suggest that patients are struggling to access in-person abortion services and may turn to self-managed abortion as a result. However, to date there has been no systematic assessment of this possibility.
What this study adds
What this study adds
Our study provides the best evidence to date that demand for self-managed medication abortion provided using online telemedicine increased following the emergence of the COVID-19 pandemic.
The largest increases were observed in countries where medication abortion is provided mainly in hospitals and where travel restrictions were most stringent. By contrast, in the one country that implemented fully remote services, demand for self-managed abortion declined almost to zero.
Our findings demonstrate the urgent need for policymakers to expand access to telemedicine models of medication abortion within the formal healthcare setting.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: ARAA and JES have received grant support from the Society of Family Planning and infrastructure support from the National Institutes of Health. The authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. RG is Founder and Director of Women on Web. The authors declare no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study was supported in part by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH through Center Grant P2CHD042849, awarded to the Population Research Center at the University of Texas at Austin. The funder played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors are completely independent from the funding sources. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Texas at Austin Institutional Review Board reviewed the study protocol and declared the use of pre-collected, fully de-identified data exempt from the need for approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No additional data are available. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.
